RxDoctor Payments Data

Jonathan Krant

Rheumatology · Peterborough, NHNPI 1023165172

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $257,670 of the $327,818 with a category attached, or 78.6%. AbbVie accounts for 64.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $74,295 and has fallen 95.5% since, to $3,341 in 2025. Among rheumatology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$327,818in general payments, 2019–2025

Across 783 payments — averaging $418.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$213K
  • Amgen$64K
  • Novartis$38K
  • Boehringer Ingelheim International GmbH$4K
  • Vertex$2K
  • Johnson & Johnson$1K
  • plus $6K from 25 others
$170,890in research payments, 2019–2025

Across 44 payments — averaging $3883.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$145K
  • Eli Lilly$26K

What the payments were for

  • Consulting fees$26,7268%
  • Speaking & faculty fees$257,67079%
  • Travel & lodging$27,9849%
  • Food & beverage$15,2345%
  • Education$2040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$327,818 in reported general payments places this provider in the 95th percentile of 48 rheumatology providers in New Hampshire.

See all rheumatology providers in New Hampshire

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$105,099
Orencia ClickjectAbatacept17$101,345
BenlystaBelimumab11$52,373
Methylprednisolone54$1,129
Hydroxychloroquine Sulfate30$944
Pregabalin29$369
Duloxetine Hcl24$294
Prednisone55$287
MethotrexateMethotrexate Sodium20$233
Gabapentin14$148
Naproxen11$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$155$52,37311 claims
Dr.reddy's Laboratories,inc.Pregabalin$580$36929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 rheumatology providers in New Hampshire.

Other rheumatology in Peterborough

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →